drugset / Trial / NCT03215264
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Timeline
- Start
- 2017-10-02
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | 3 mg | — |
| Subject | Entinostat | Small molecule | 5 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 1200 mg | — |
| Background | Regorafenib | Small molecule | 160 mg | — |